JP2012532888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532888A5 JP2012532888A5 JP2012519764A JP2012519764A JP2012532888A5 JP 2012532888 A5 JP2012532888 A5 JP 2012532888A5 JP 2012519764 A JP2012519764 A JP 2012519764A JP 2012519764 A JP2012519764 A JP 2012519764A JP 2012532888 A5 JP2012532888 A5 JP 2012532888A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidin
- pyrazolo
- carboxamide
- pyrimidine
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 254
- 150000001875 compounds Chemical class 0.000 claims description 104
- -1 2,5-difluorophenyl Chemical group 0.000 claims description 95
- 125000001424 substituent group Chemical group 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims description 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 101100062121 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyc-1 gene Proteins 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
- XMRIUEGHBZTNND-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC=NC2=C(C(=O)N)C=NN21 XMRIUEGHBZTNND-UHFFFAOYSA-N 0.000 claims 47
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 3
- UEHKWTJSMNTTCC-SJKOYZFVSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-N-[(2R)-2-hydroxypropyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@@H](O)CNC(=O)C1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1 UEHKWTJSMNTTCC-SJKOYZFVSA-N 0.000 claims 2
- CYJPVTPYPTUQAC-HYSRAYMDSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-(4-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(C)(O)CCC1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 CYJPVTPYPTUQAC-HYSRAYMDSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- LJCJRRKKAKAKRV-UHFFFAOYSA-N (2-amino-2-methylpropyl) 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical group CC(C)(N)COC(=O)CCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 LJCJRRKKAKAKRV-UHFFFAOYSA-N 0.000 claims 1
- GNFIVOXDMLGGJJ-MRXNPFEDSA-N 1-[2-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazol-1-yl]ethyl]imidazolidin-2-one Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=CC=NN1CCN1C(NCC1)=O GNFIVOXDMLGGJJ-MRXNPFEDSA-N 0.000 claims 1
- PFTUHNICIXICMP-LJQANCHMSA-N 1-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbonyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 PFTUHNICIXICMP-LJQANCHMSA-N 0.000 claims 1
- HUMIANOGLZOVBP-MRXNPFEDSA-N 1-[[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbonyl]amino]cyclopropane-1-carboxylic acid Chemical compound C1=NN2C=CC(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)=NC2=C1C(=O)NC1(C(=O)O)CC1 HUMIANOGLZOVBP-MRXNPFEDSA-N 0.000 claims 1
- BNDQCVSMOIBZCI-GOSISDBHSA-N 1-cyclopropyl-5-[(2r)-2-[3-fluoro-5-(2-methoxyethoxy)phenyl]pyrrolidin-1-yl]pyrazole Chemical compound COCCOC1=CC(F)=CC([C@@H]2N(CCC2)C=2N(N=CC=2)C2CC2)=C1 BNDQCVSMOIBZCI-GOSISDBHSA-N 0.000 claims 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- HYQUCWQCNZSJRP-HXUWFJFHSA-N 2-[1-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbonyl]piperidin-4-yl]acetic acid Chemical compound C1CC(CC(=O)O)CCN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 HYQUCWQCNZSJRP-HXUWFJFHSA-N 0.000 claims 1
- 125000006016 2-bromoethoxy group Chemical group 0.000 claims 1
- 125000006012 2-chloroethoxy group Chemical group 0.000 claims 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- ZZZONOLAOQEATF-QGZVFWFLSA-N 4-[[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazol-1-yl]methyl]-1-methylimidazole Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=CC=NN1CC=1N=CN(C=1)C ZZZONOLAOQEATF-QGZVFWFLSA-N 0.000 claims 1
- YYWBCTXPSKWIQX-QGZVFWFLSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-1-[2-(1H-imidazol-5-yl)ethyl]pyrazole Chemical compound N1C=NC(=C1)CCN1N=CC=C1N1[C@H](CCC1)C1=C(C=CC(=C1)F)F YYWBCTXPSKWIQX-QGZVFWFLSA-N 0.000 claims 1
- WGQPLEIMNLEFTL-QGZVFWFLSA-N 5-[(2R)-2-(5-fluoro-1-methyl-2-oxopyridin-3-yl)pyrrolidin-1-yl]-N-(5-hydroxypyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CN1C=C(F)C=C([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)NC2=NC=C(O)C=C2)C1=O WGQPLEIMNLEFTL-QGZVFWFLSA-N 0.000 claims 1
- OTCSCPHWCZZRDC-LBXVMSDZSA-N 5-[(2R)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-N-(4-methylsulfonylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@H]1CCCN1C1=NC2=C(C=NN2C=C1)C(=O)NC1CCC(CC1)S(C)(=O)=O OTCSCPHWCZZRDC-LBXVMSDZSA-N 0.000 claims 1
- DUJWGLCTYAWISR-MRXNPFEDSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n,n-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N(C)C)=CC(F)=CC=C1F DUJWGLCTYAWISR-MRXNPFEDSA-N 0.000 claims 1
- XWDLDVQSUXONBG-LJQANCHMSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-(3-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=CC=CN=C1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 XWDLDVQSUXONBG-LJQANCHMSA-N 0.000 claims 1
- IXPTZPMMOJWPBZ-JBBXEZCESA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2r,3s)-1,3-dihydroxybutan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@H](CO)[C@@H](O)C)=CC(F)=CC=C1F IXPTZPMMOJWPBZ-JBBXEZCESA-N 0.000 claims 1
- PXRHKVCFGOFIIB-SUMWQHHRSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s)-2,3-dihydroxypropoxy]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC[C@@H](O)CO)=CC(F)=CC=C1F PXRHKVCFGOFIIB-SUMWQHHRSA-N 0.000 claims 1
- GSSDAQWHOJFZRE-SUMWQHHRSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s)-2,3-dihydroxypropyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC[C@H](O)CO)=CC(F)=CC=C1F GSSDAQWHOJFZRE-SUMWQHHRSA-N 0.000 claims 1
- IXPTZPMMOJWPBZ-OCBCSQNSSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s,3r)-1,3-dihydroxybutan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@@H](CO)[C@H](O)C)=CC(F)=CC=C1F IXPTZPMMOJWPBZ-OCBCSQNSSA-N 0.000 claims 1
- IXPTZPMMOJWPBZ-UYHISHBKSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[(2s,3s)-1,3-dihydroxybutan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@@H](CO)[C@@H](O)C)=CC(F)=CC=C1F IXPTZPMMOJWPBZ-UYHISHBKSA-N 0.000 claims 1
- OMWFIVWGJYQGKO-GOSISDBHSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[1-(methanesulfonamido)-2-methylpropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(CNS(C)(=O)=O)C)=CC(F)=CC=C1F OMWFIVWGJYQGKO-GOSISDBHSA-N 0.000 claims 1
- FUHAANUNQWUCBT-OAHLLOKOSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CC(F)=CC=C1F FUHAANUNQWUCBT-OAHLLOKOSA-N 0.000 claims 1
- MBZCRLUONJJYJU-OAHLLOKOSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC(F)=CC=C1F MBZCRLUONJJYJU-OAHLLOKOSA-N 0.000 claims 1
- JBTQGTQNCVBRNY-CQSZACIVSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1F JBTQGTQNCVBRNY-CQSZACIVSA-N 0.000 claims 1
- PEUXFCOIQKEZCE-CQSZACIVSA-N 5-[(2r)-2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(2-hydroxyethoxy)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOCCO)=CC(F)=CN=C1Cl PEUXFCOIQKEZCE-CQSZACIVSA-N 0.000 claims 1
- CXFMNHBMKOIQLW-QGZVFWFLSA-N 5-[(2r)-2-(2-chloro-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[2-[(2-methylpropan-2-yl)oxy]ethoxy]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOCCOC(C)(C)C)=CC(F)=CN=C1Cl CXFMNHBMKOIQLW-QGZVFWFLSA-N 0.000 claims 1
- YFZGYNMBIQOANX-TWOQFEAHSA-N 5-[(2r)-2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[(1s,3s)-3-hydroxycyclopentyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CCC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N[C@@H]4C[C@@H](O)CC4)C=NN3C=C2)CCC1 YFZGYNMBIQOANX-TWOQFEAHSA-N 0.000 claims 1
- ISGDOVGHVRHZFY-AFMYVXGZSA-N 5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(O)CCC1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=CC=3)C=CN2N=C1 ISGDOVGHVRHZFY-AFMYVXGZSA-N 0.000 claims 1
- MLIFTZTWMYPZAL-OAHLLOKOSA-N 5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CC=CC(F)=C1 MLIFTZTWMYPZAL-OAHLLOKOSA-N 0.000 claims 1
- LZJSAQIUAQDIAJ-CQSZACIVSA-N 5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC=CC(F)=C1 LZJSAQIUAQDIAJ-CQSZACIVSA-N 0.000 claims 1
- GSRZAXNWBZUUOT-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-1-methyl-2-oxopyridin-3-yl)pyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CC(F)=CN(C)C1=O GSRZAXNWBZUUOT-MRXNPFEDSA-N 0.000 claims 1
- BBRVRCQHOJGIEM-QGZVFWFLSA-N 5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]-n-(2-hydroxy-2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCC(C)(C)O)C=NN3C=C2)CCC1 BBRVRCQHOJGIEM-QGZVFWFLSA-N 0.000 claims 1
- IHLOJSUOOQFANO-HXUWFJFHSA-N 5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]-n-(2-morpholin-4-ylethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCCN4CCOCC4)C=NN3C=C2)CCC1 IHLOJSUOOQFANO-HXUWFJFHSA-N 0.000 claims 1
- DCLFPTZRYFZAKO-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(1-fluoro-2-methylpropan-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC(C)(C)CF)C=NN3C=C2)CCC1 DCLFPTZRYFZAKO-MRXNPFEDSA-N 0.000 claims 1
- YLAKIDRGVDYWAA-OAHLLOKOSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(2-hydroxyethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCCO)C=NN3C=C2)CCC1 YLAKIDRGVDYWAA-OAHLLOKOSA-N 0.000 claims 1
- VTUVGNKQBUVKIW-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(3-hydroxypropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCCCO)C=NN3C=C2)CCC1 VTUVGNKQBUVKIW-MRXNPFEDSA-N 0.000 claims 1
- WRXZQYJJPXFOIB-LADRWXRNSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CCC(O)CC4)C=NN3C=C2)CCC1 WRXZQYJJPXFOIB-LADRWXRNSA-N 0.000 claims 1
- KUMKUBXRGRIPEY-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-(5-methyl-1h-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC=4NN=C(C)C=4)C=NN3C=C2)CCC1 KUMKUBXRGRIPEY-MRXNPFEDSA-N 0.000 claims 1
- REPYLSGOOOJRSV-CQSZACIVSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CC(F)=CN=C1OC REPYLSGOOOJRSV-CQSZACIVSA-N 0.000 claims 1
- WAAWHVXSMHHZCZ-CQSZACIVSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC(F)=CN=C1OC WAAWHVXSMHHZCZ-CQSZACIVSA-N 0.000 claims 1
- XIDPBDLUUJOTDD-CYBMUJFWSA-N 5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(N)=O)C=NN3C=C2)CCC1 XIDPBDLUUJOTDD-CYBMUJFWSA-N 0.000 claims 1
- AYXUQBNBYRQZDH-OAHLLOKOSA-N 5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC(F)=CN=C1C AYXUQBNBYRQZDH-OAHLLOKOSA-N 0.000 claims 1
- PMKFFRXMNWSTLH-QGZVFWFLSA-N 5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CC(F)=CN=C1C PMKFFRXMNWSTLH-QGZVFWFLSA-N 0.000 claims 1
- UEWLKIVHINNLJX-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C=CC(N3[C@H](CCC3)C=3C=C(F)C=NC=3)=NC2=C1C(=O)NC1(C)CC1 UEWLKIVHINNLJX-MRXNPFEDSA-N 0.000 claims 1
- LASRMRBYBVIFQT-LJQANCHMSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(1-methylsulfonylpiperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 LASRMRBYBVIFQT-LJQANCHMSA-N 0.000 claims 1
- KJYXTMLZCPHUAV-IAQYHMDHSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[(2r)-1,1,1-trifluoropropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@H](C)C(F)(F)F)=CN=CC(F)=C1 KJYXTMLZCPHUAV-IAQYHMDHSA-N 0.000 claims 1
- ONENEBSQEBHUSO-CQSZACIVSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-methoxypyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NOC)=CN=CC(F)=C1 ONENEBSQEBHUSO-CQSZACIVSA-N 0.000 claims 1
- AOJFJIKCNFEJMA-CQSZACIVSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CN=CC(F)=C1 AOJFJIKCNFEJMA-CQSZACIVSA-N 0.000 claims 1
- KOZAUWSJLNLRBA-MRXNPFEDSA-N 5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CN=CC(F)=C1 KOZAUWSJLNLRBA-MRXNPFEDSA-N 0.000 claims 1
- LTWRCYLYOAZNPD-FQNRMIAFSA-N 5-[(2r)-2-[2-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1OCC(O)CO LTWRCYLYOAZNPD-FQNRMIAFSA-N 0.000 claims 1
- JDIGZDKHSLPKGP-KPMSDPLLSA-N 5-[(2r)-2-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(N)=O)C=NN3C=C2)CCC1 JDIGZDKHSLPKGP-KPMSDPLLSA-N 0.000 claims 1
- UGWUALPBTGHKQH-FBMWCMRBSA-N 5-[(2r)-2-[3-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC(OCC(O)CO)=C1 UGWUALPBTGHKQH-FBMWCMRBSA-N 0.000 claims 1
- QXACJSRSZMVUQK-WHCXFUJUSA-N 5-[(2r)-2-[3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC(F)=CC([C@@H]2N(CCC2)C2=NC3=C(C(N)=O)C=NN3C=C2)=C1 QXACJSRSZMVUQK-WHCXFUJUSA-N 0.000 claims 1
- OPRRDZXAVINFQM-MRXNPFEDSA-N 5-[(2r)-2-[5-fluoro-2-(2-methoxyethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COCCOC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(N)=O)C=NN3C=C2)CCC1 OPRRDZXAVINFQM-MRXNPFEDSA-N 0.000 claims 1
- CZZPKZAXQSRAJE-LJQANCHMSA-N 5-[(2r)-2-[5-fluoro-2-(2-morpholin-4-ylethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1OCCN1CCOCC1 CZZPKZAXQSRAJE-LJQANCHMSA-N 0.000 claims 1
- OVDQQFSDDWEASL-CQSZACIVSA-N 5-[(2r)-2-[5-fluoro-2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)N)=CC(F)=CC=C1C(F)(F)F OVDQQFSDDWEASL-CQSZACIVSA-N 0.000 claims 1
- TUPCMOPJDADTAY-UKRRQHHQSA-N 5-[(2r,4r)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]-n-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2C[C@@H](O)CN2C=2C=CN3N=CC(=C3N=2)C(=O)NC)=CC=CC(F)=C1 TUPCMOPJDADTAY-UKRRQHHQSA-N 0.000 claims 1
- VEFAIJAFTRTKSA-DOTOQJQBSA-N 5-[(2r,4s)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2C[C@H](O)CN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CC=CC(F)=C1 VEFAIJAFTRTKSA-DOTOQJQBSA-N 0.000 claims 1
- HHFHBMCHRPJYLX-DOTOQJQBSA-N 5-[(2r,5s)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl]-n-(1-methylcyclopropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C=CC(N3[C@H](CC[C@H]3CO)C=3C=C(F)C=NC=3)=NC2=C1C(=O)NC1(C)CC1 HHFHBMCHRPJYLX-DOTOQJQBSA-N 0.000 claims 1
- AROVXDKGPGGRBP-DIOULYMOSA-N 5-[(2r,5s)-2-(5-fluoropyridin-3-yl)-5-(hydroxymethyl)pyrrolidin-1-yl]-n-[(2r)-1,1,1-trifluoropropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CC[C@@H](CO)N2C=2C=CN3N=CC(=C3N=2)C(=O)N[C@H](C)C(F)(F)F)=CN=CC(F)=C1 AROVXDKGPGGRBP-DIOULYMOSA-N 0.000 claims 1
- JPAYSBNMHYNPLA-KRYHZZBUSA-N 5-[(2s,5r)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-n-[(2s)-1,1,1-trifluoropropan-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@@H]2N([C@](CC2)(C)CO)C=2C=CN3N=CC(=C3N=2)C(=O)N[C@@H](C)C(F)(F)F)=CN=CC(F)=C1 JPAYSBNMHYNPLA-KRYHZZBUSA-N 0.000 claims 1
- DYTJJBIQSYEXQH-UTKZUKDTSA-N 5-[(2s,5r)-5-(5-fluoropyridin-3-yl)-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl]-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@@H]2N([C@](CC2)(C)CO)C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)C)=CN=CC(F)=C1 DYTJJBIQSYEXQH-UTKZUKDTSA-N 0.000 claims 1
- RKVKRYPLPNWYSE-OAHLLOKOSA-N 5-[(5r)-5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCC(N2C2=NC3=C(C(N)=O)C=NN3C=C2)(C)C)=CC(F)=CC=C1F RKVKRYPLPNWYSE-OAHLLOKOSA-N 0.000 claims 1
- ZYIYWAPOCQBZSM-UHFFFAOYSA-N 5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]-n-[2-(4-hydroxypiperidin-1-yl)ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(O)CCN1CCNC(=O)C1=C2N=C(N3C(CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 ZYIYWAPOCQBZSM-UHFFFAOYSA-N 0.000 claims 1
- COJJJJKXTCQCLW-UHFFFAOYSA-N 5-[2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CCC1=NC=C(F)C=C1C1N(C2=NC3=C(C(=O)NC4CCC(O)CC4)C=NN3C=C2)CCC1 COJJJJKXTCQCLW-UHFFFAOYSA-N 0.000 claims 1
- GYPXDOPFEWTHRF-CTWPCTMYSA-N 5-[2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]-N-[(2R)-2-hydroxycyclopentyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=C(C=C(F)C=N1)C1CCCN1C1=NC2=C(C=NN2C=C1)C(=O)NC1CCC[C@H]1O GYPXDOPFEWTHRF-CTWPCTMYSA-N 0.000 claims 1
- RKRWQXHCILAOQU-UHFFFAOYSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(2-hydroxycyclopentyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OC1CCCC1NC(=O)C1=C2N=C(N3C(CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 RKRWQXHCILAOQU-UHFFFAOYSA-N 0.000 claims 1
- WWRZXXZWDNGWCD-UHFFFAOYSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(3-hydroxy-2,2-dimethylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N=1C2=C(C(=O)NCC(C)(CO)C)C=NN2C=CC=1N1CCCC1C1=CN=CC(F)=C1 WWRZXXZWDNGWCD-UHFFFAOYSA-N 0.000 claims 1
- CNSDQPQILIEBIM-UHFFFAOYSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-(4-hydroxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CC(O)CCC1NC(=O)C1=C2N=C(N3C(CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 CNSDQPQILIEBIM-UHFFFAOYSA-N 0.000 claims 1
- RKRWQXHCILAOQU-GVYDCBATSA-N 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]-n-[(1r,2r)-2-hydroxycyclopentyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O[C@@H]1CCC[C@H]1NC(=O)C1=C2N=C(N3C(CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 RKRWQXHCILAOQU-GVYDCBATSA-N 0.000 claims 1
- DBAVNXWRJILFRQ-AKCHCHLHSA-N C1C[C@@H](C(=O)O)CC[C@@H]1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 Chemical compound C1C[C@@H](C(=O)O)CC[C@@H]1NC(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 DBAVNXWRJILFRQ-AKCHCHLHSA-N 0.000 claims 1
- QILHXRYEOIFMNQ-OAQYLSRUSA-N CN1CCN(CCN2N(C=CC(N(CCC3)[C@H]3C(C=C(C=C3)F)=C3F)=N3)C3=CC2)CC1 Chemical compound CN1CCN(CCN2N(C=CC(N(CCC3)[C@H]3C(C=C(C=C3)F)=C3F)=N3)C3=CC2)CC1 QILHXRYEOIFMNQ-OAQYLSRUSA-N 0.000 claims 1
- ZQJUUOXBTWYBJE-QGZVFWFLSA-N [5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxy-3-methylazetidin-1-yl)methanone Chemical compound C1C(C)(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 ZQJUUOXBTWYBJE-QGZVFWFLSA-N 0.000 claims 1
- OVSWBIYHLZFTTJ-QGZVFWFLSA-N [5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 OVSWBIYHLZFTTJ-QGZVFWFLSA-N 0.000 claims 1
- OKICNWNFGLYZRW-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxy-3-methylazetidin-1-yl)methanone Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N4CC(C)(O)C4)C=NN3C=C2)CCC1 OKICNWNFGLYZRW-MRXNPFEDSA-N 0.000 claims 1
- KEMAQYFMSWCNPP-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N4CC(O)C4)C=NN3C=C2)CCC1 KEMAQYFMSWCNPP-MRXNPFEDSA-N 0.000 claims 1
- DIVNKYZMVMAVDL-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound CC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)N4CC(O)C4)C=NN3C=C2)CCC1 DIVNKYZMVMAVDL-QGZVFWFLSA-N 0.000 claims 1
- ZBAKBPQBWVZHSS-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxy-3-methylazetidin-1-yl)methanone Chemical compound C1C(C)(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 ZBAKBPQBWVZHSS-MRXNPFEDSA-N 0.000 claims 1
- IAQOHRSJLFSNIO-MRXNPFEDSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C1C(O)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 IAQOHRSJLFSNIO-MRXNPFEDSA-N 0.000 claims 1
- ZTUAEBXOYDCUHH-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-(3-methoxyazetidin-1-yl)methanone Chemical compound C1C(OC)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 ZTUAEBXOYDCUHH-QGZVFWFLSA-N 0.000 claims 1
- YWPVOJJFDPUXIP-DOTOQJQBSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-[(3s)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound C1[C@@H](O)CCN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 YWPVOJJFDPUXIP-DOTOQJQBSA-N 0.000 claims 1
- VCAFMQVDMYUXAD-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-[3-(hydroxymethyl)azetidin-1-yl]methanone Chemical compound C1C(CO)CN1C(=O)C1=C2N=C(N3[C@H](CCC3)C=3C=C(F)C=NC=3)C=CN2N=C1 VCAFMQVDMYUXAD-QGZVFWFLSA-N 0.000 claims 1
- RFEWPNNVHIQMAM-GOSISDBHSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-piperidin-1-ylmethanone Chemical compound FC1=CN=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)N4CCCCC4)C=NN3C=C2)=C1 RFEWPNNVHIQMAM-GOSISDBHSA-N 0.000 claims 1
- VICTZKCFLVXPBL-QGZVFWFLSA-N [5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-pyrrolidin-1-ylmethanone Chemical compound FC1=CN=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)N4CCCC4)C=NN3C=C2)=C1 VICTZKCFLVXPBL-QGZVFWFLSA-N 0.000 claims 1
- CJXSUHUGXGYYSY-UHFFFAOYSA-N azetidin-1-yl-[5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]methanone Chemical compound FC1=CN=CC(C2N(CCC2)C2=NC3=C(C(=O)N4CCC4)C=NN3C=C2)=C1 CJXSUHUGXGYYSY-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- IXPSNGNVZSOSLS-MRXNPFEDSA-N n-(1-fluoro-2-methylpropan-2-yl)-5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(CF)C)=CN=CC(F)=C1 IXPSNGNVZSOSLS-MRXNPFEDSA-N 0.000 claims 1
- HGBUMXKTCONBMP-FQNRMIAFSA-N n-(2,3-dihydroxypropyl)-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NCC(O)CO)C=NN3C=C2)CCC1 HGBUMXKTCONBMP-FQNRMIAFSA-N 0.000 claims 1
- RWIYPTPMXPGFTG-CQSZACIVSA-N n-(2-chloroethyl)-5-[(2r)-2-(5-fluoro-2-oxo-1h-pyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CNC(=O)C([C@@H]2N(CCC2)C2=NC3=C(C(=O)NCCCl)C=NN3C=C2)=C1 RWIYPTPMXPGFTG-CQSZACIVSA-N 0.000 claims 1
- VMUKQRHNARMWLU-OAHLLOKOSA-N n-(3-aminopropyl)-5-[(2r)-2-(5-fluoro-2-oxo-1h-pyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NCCCN)=CC(F)=CNC1=O VMUKQRHNARMWLU-OAHLLOKOSA-N 0.000 claims 1
- ZOHMFCHQNJCASG-RHSMWYFYSA-N n-[(2r)-2,3-dihydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@@H](O)CO)C=NN3C=C2)CCC1 ZOHMFCHQNJCASG-RHSMWYFYSA-N 0.000 claims 1
- IVHDXWQQZJTUMV-CXAGYDPISA-N n-[(2r)-2,3-dihydroxypropyl]-5-[(2r)-2-[5-fluoro-2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC[C@@H](O)CO)=CC(F)=CC=C1C(F)(F)F IVHDXWQQZJTUMV-CXAGYDPISA-N 0.000 claims 1
- ZOHMFCHQNJCASG-WMLDXEAASA-N n-[(2s)-2,3-dihydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@H](O)CO)C=NN3C=C2)CCC1 ZOHMFCHQNJCASG-WMLDXEAASA-N 0.000 claims 1
- HGBUMXKTCONBMP-XJKSGUPXSA-N n-[(2s)-2,3-dihydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@H](O)CO)C=NN3C=C2)CCC1 HGBUMXKTCONBMP-XJKSGUPXSA-N 0.000 claims 1
- IVHDXWQQZJTUMV-SUMWQHHRSA-N n-[(2s)-2,3-dihydroxypropyl]-5-[(2r)-2-[5-fluoro-2-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC[C@H](O)CO)=CC(F)=CC=C1C(F)(F)F IVHDXWQQZJTUMV-SUMWQHHRSA-N 0.000 claims 1
- FZWUREXRAHZCKC-CZUORRHYSA-N n-[(2s)-3-chloro-2-hydroxypropyl]-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC[C@H](O)CCl)C=NN3C=C2)CCC1 FZWUREXRAHZCKC-CZUORRHYSA-N 0.000 claims 1
- PKQNMQSZDCVFLD-GOSISDBHSA-N n-cyclobutyl-5-[(2r)-2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CCC4)C=NN3C=C2)CCC1 PKQNMQSZDCVFLD-GOSISDBHSA-N 0.000 claims 1
- QVEBEDUBSUAZSH-UHFFFAOYSA-N n-cyclobutyl-5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CN=CC(C2N(CCC2)C2=NC3=C(C(=O)NC4CCC4)C=NN3C=C2)=C1 QVEBEDUBSUAZSH-UHFFFAOYSA-N 0.000 claims 1
- FUZYGEZQKAHUFX-QGZVFWFLSA-N n-cyclopropyl-5-[(2r)-2-(3-fluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CC=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 FUZYGEZQKAHUFX-QGZVFWFLSA-N 0.000 claims 1
- MQONFTAVRMZHBN-QGZVFWFLSA-N n-cyclopropyl-5-[(2r)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 MQONFTAVRMZHBN-QGZVFWFLSA-N 0.000 claims 1
- JKTPHVQLCMLNMW-MRXNPFEDSA-N n-cyclopropyl-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 JKTPHVQLCMLNMW-MRXNPFEDSA-N 0.000 claims 1
- ZBJDRRTVBWHVAP-MRXNPFEDSA-N n-cyclopropyl-5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CN=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 ZBJDRRTVBWHVAP-MRXNPFEDSA-N 0.000 claims 1
- ZGPOATYOAANSTK-LRTDYKAYSA-N n-cyclopropyl-5-[(2r)-2-[2-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(O)COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 ZGPOATYOAANSTK-LRTDYKAYSA-N 0.000 claims 1
- SVIHXEVVNNRVEM-BDPMCISCSA-N n-cyclopropyl-5-[(2r)-2-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 SVIHXEVVNNRVEM-BDPMCISCSA-N 0.000 claims 1
- YDZSAJWQPHVDHL-UUSAFJCLSA-N n-cyclopropyl-5-[(2r)-2-[3-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OCC(O)COC1=CC(F)=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 YDZSAJWQPHVDHL-UUSAFJCLSA-N 0.000 claims 1
- HLAYAPGHRGSWFL-LWMIZPGFSA-N n-cyclopropyl-5-[(2r)-2-[3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC(F)=CC([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=C1 HLAYAPGHRGSWFL-LWMIZPGFSA-N 0.000 claims 1
- DXRCURBJOZPWHE-JOCHJYFZSA-N n-cyclopropyl-5-[(2r)-2-[5-fluoro-2-(2-morpholin-4-ylethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@@H]2N(CCC2)C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)=CC(F)=CC=C1OCCN1CCOCC1 DXRCURBJOZPWHE-JOCHJYFZSA-N 0.000 claims 1
- DHEFBJXZYSKWIF-NVXWUHKLSA-N n-cyclopropyl-5-[(2r,4r)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N1([C@H](C[C@H](C1)O)C=1C=C(F)C=CC=1)C(=NC1=2)C=CN1N=CC=2C(=O)NC1CC1 DHEFBJXZYSKWIF-NVXWUHKLSA-N 0.000 claims 1
- HQCZHKJSSABUNL-GOSISDBHSA-N n-cyclopropyl-5-[(5r)-5-(2,5-difluorophenyl)-2,2-dimethylpyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N1([C@H](CCC1(C)C)C=1C(=CC=C(F)C=1)F)C(=NC1=2)C=CN1N=CC=2C(=O)NC1CC1 HQCZHKJSSABUNL-GOSISDBHSA-N 0.000 claims 1
- HNJJBTOZBLOWTO-UHFFFAOYSA-N n-cyclopropyl-5-[2-(2-ethyl-5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CCC1=NC=C(F)C=C1C1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 HNJJBTOZBLOWTO-UHFFFAOYSA-N 0.000 claims 1
- XCCJJNIKWGXTSP-UHFFFAOYSA-N n-cyclopropyl-5-[2-(5-fluoro-2-methylpyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=NC=C(F)C=C1C1N(C2=NC3=C(C(=O)NC4CC4)C=NN3C=C2)CCC1 XCCJJNIKWGXTSP-UHFFFAOYSA-N 0.000 claims 1
- XDTRTPIHJGKMHO-QGZVFWFLSA-N n-tert-butyl-5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CC(F)=CC=C1F XDTRTPIHJGKMHO-QGZVFWFLSA-N 0.000 claims 1
- CABSRBXIZHPYSN-MRXNPFEDSA-N n-tert-butyl-5-[(2r)-2-(5-fluoro-1-methyl-2-oxopyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound O=C1N(C)C=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC(C)(C)C)C=NN3C=C2)CCC1 CABSRBXIZHPYSN-MRXNPFEDSA-N 0.000 claims 1
- ACAZGFYJHFUFNU-MRXNPFEDSA-N n-tert-butyl-5-[(2r)-2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=NC=C(F)C=C1[C@@H]1N(C2=NC3=C(C(=O)NC(C)(C)C)C=NN3C=C2)CCC1 ACAZGFYJHFUFNU-MRXNPFEDSA-N 0.000 claims 1
- SPGMDULIPMJULM-OAHLLOKOSA-N n-tert-butyl-5-[(2r)-2-(5-fluoro-2-oxo-1h-pyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CC(F)=CNC1=O SPGMDULIPMJULM-OAHLLOKOSA-N 0.000 claims 1
- BOGXBCHXRCHFDS-MRXNPFEDSA-N n-tert-butyl-5-[(2r)-2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2CCCN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CN=CC(F)=C1 BOGXBCHXRCHFDS-MRXNPFEDSA-N 0.000 claims 1
- JSSACTCBXIXNAA-NVXWUHKLSA-N n-tert-butyl-5-[(2r,4r)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1([C@H]2C[C@@H](O)CN2C=2C=CN3N=CC(=C3N=2)C(=O)NC(C)(C)C)=CC=CC(F)=C1 JSSACTCBXIXNAA-NVXWUHKLSA-N 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- LKKQICCORQINHH-UHFFFAOYSA-N 3-fluoro-3H-pyridin-6-one Chemical group FC1C=CC(=O)N=C1 LKKQICCORQINHH-UHFFFAOYSA-N 0.000 description 4
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22419609P | 2009-07-09 | 2009-07-09 | |
| US61/224,196 | 2009-07-09 | ||
| US34676710P | 2010-05-20 | 2010-05-20 | |
| US61/346,767 | 2010-05-20 | ||
| PCT/US2010/041538 WO2011006074A1 (en) | 2009-07-09 | 2010-07-09 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002767A Division JP6114765B2 (ja) | 2009-07-09 | 2015-01-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532888A JP2012532888A (ja) | 2012-12-20 |
| JP2012532888A5 true JP2012532888A5 (https=) | 2013-08-08 |
| JP5716021B2 JP5716021B2 (ja) | 2015-05-13 |
Family
ID=42732102
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519764A Expired - Fee Related JP5716021B2 (ja) | 2009-07-09 | 2010-07-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JP2015002767A Expired - Fee Related JP6114765B2 (ja) | 2009-07-09 | 2015-01-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JP2017020927A Withdrawn JP2017082004A (ja) | 2009-07-09 | 2017-02-08 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002767A Expired - Fee Related JP6114765B2 (ja) | 2009-07-09 | 2015-01-09 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
| JP2017020927A Withdrawn JP2017082004A (ja) | 2009-07-09 | 2017-02-08 | ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US8791123B2 (https=) |
| EP (2) | EP2451812B1 (https=) |
| JP (3) | JP5716021B2 (https=) |
| KR (3) | KR101933123B1 (https=) |
| CN (3) | CN106008523B (https=) |
| AR (1) | AR077468A1 (https=) |
| AU (1) | AU2010271270C1 (https=) |
| CA (2) | CA3013618C (https=) |
| CL (1) | CL2012000059A1 (https=) |
| CO (1) | CO6612183A2 (https=) |
| CR (2) | CR20120065A (https=) |
| ES (2) | ES2655899T3 (https=) |
| IL (1) | IL217414A (https=) |
| MX (2) | MX364157B (https=) |
| MY (1) | MY162180A (https=) |
| NZ (1) | NZ598086A (https=) |
| RU (2) | RU2016114128A (https=) |
| SG (2) | SG177553A1 (https=) |
| TW (1) | TWI503321B (https=) |
| UY (1) | UY32782A (https=) |
| WO (1) | WO2011006074A1 (https=) |
| ZA (1) | ZA201200982B (https=) |
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| EP2348860B1 (en) * | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| MA34969B1 (fr) * | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| CA2835835C (en) | 2011-05-13 | 2019-04-02 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
| CN106496173A (zh) | 2011-09-30 | 2017-03-15 | 沃泰克斯药物股份有限公司 | 用于制备可用作atr激酶抑制剂的化合物的方法 |
| CN108685922A (zh) | 2011-09-30 | 2018-10-23 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| CN104302649B (zh) * | 2012-03-09 | 2017-06-23 | 莱西肯医药有限公司 | 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 |
| CN108478577A (zh) | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| RS55593B1 (sr) * | 2012-11-13 | 2017-06-30 | Array Biopharma Inc | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola |
| WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| MX374242B (es) * | 2012-11-13 | 2025-03-05 | Array Biopharma Inc | Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa. |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| AU2014219855B2 (en) * | 2013-02-19 | 2017-09-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| EP3628749A1 (en) | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 |
| TWI731317B (zh) * | 2013-12-10 | 2021-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| WO2015104602A2 (en) | 2014-01-08 | 2015-07-16 | Wockhardt Limited | A process for the preparation of anagliptin and its intermediates thereof |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| WO2015150887A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Process for the preparation of anagliptin or its salts |
| US20150324646A1 (en) | 2014-05-08 | 2015-11-12 | Brown University | Navigation methods and apparatus for the visually impaired |
| MA40434B1 (fr) | 2014-05-15 | 2019-09-30 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka |
| JP2017516850A (ja) | 2014-05-23 | 2017-06-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物 |
| SG11201607895PA (en) | 2014-05-28 | 2016-12-29 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
| MX373102B (es) | 2014-06-05 | 2020-04-17 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo. |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| US10399959B2 (en) * | 2014-08-18 | 2019-09-03 | Ono Pharmaceutical Co., Ltd. | Acid-addition salt of Trk-inhibiting compound |
| LT3194407T (lt) * | 2014-09-17 | 2020-01-27 | Oncodesign S.A. | Makrocikliniai rip2 kinazės inhibitoriai |
| EP4406616A3 (en) | 2014-11-06 | 2024-11-06 | Bial-R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
| CN113354649B (zh) | 2014-11-16 | 2024-12-10 | 阵列生物制药公司 | 一种新的晶型 |
| CA2971024C (en) * | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| HK1253093A1 (zh) | 2015-06-01 | 2019-06-06 | Loxo Oncology Inc. | 诊断和治疗癌症的方法 |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RU2765181C2 (ru) | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| PT3733187T (pt) | 2015-07-21 | 2024-11-08 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro |
| BR112018003588A2 (pt) | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| WO2017073706A1 (ja) * | 2015-10-30 | 2017-05-04 | 中外製薬株式会社 | ジヒドロナフト［２，３－ｂ］ベンゾフラン誘導体 |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| AU2017246547B2 (en) | 2016-04-04 | 2023-02-23 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| FI3439662T3 (fi) | 2016-04-04 | 2024-09-04 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita |
| EP3440081A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| AU2017246455B2 (en) * | 2016-04-06 | 2021-09-30 | Bial - R&D Investments, S.A. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR102530515B1 (ko) | 2016-05-05 | 2023-05-09 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도 |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS |
| KR101881650B1 (ko) * | 2016-10-02 | 2018-07-24 | 재단법인대구경북과학기술원 | 뇌유래신경성장인자를 과발현하는 우울증 동물모델 및 이의 제조방법 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| ES2896943T3 (es) * | 2016-10-28 | 2022-02-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuesto de amino pirazolopirimidina usado como inhibidor de receptores con actividad tirosina quinasa de factores neurotróficos |
| CN108003161B (zh) * | 2016-10-28 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 神经营养因子酪氨酸激酶受体抑制剂 |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| MX387969B (es) | 2017-05-22 | 2025-03-19 | Hoffmann La Roche | Composiciones y compuestos terapéuticos, y métodos para su uso. |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| CN107286070B (zh) * | 2017-07-19 | 2019-07-16 | 浙江师范大学 | (r)-2-(2,5-二氟苯基)吡咯烷的合成方法及中间体 |
| SI3658557T1 (sl) * | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| FI3661935T3 (fi) * | 2017-08-11 | 2023-01-13 | Kinaasin estäjinä käyttökelpoiset pyratsolipyrimidiinit | |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019084285A1 (en) | 2017-10-26 | 2019-05-02 | Qian Zhao | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| SG11202005237SA (en) | 2017-12-15 | 2020-07-29 | Pyramid Biosciences Inc | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| CN111936500B (zh) * | 2018-03-14 | 2023-09-01 | 重庆复尚源创医药技术有限公司 | 作为TRK激酶抑制剂的取代的(2-氮杂双环[3.1.0]己-2-基)吡唑[1,5-a]嘧啶和咪唑[1,2-b]哒嗪化合物 |
| WO2019191659A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| CN111902417B (zh) | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| CN110294761B (zh) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| JP7472103B2 (ja) | 2018-08-22 | 2024-04-22 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| KR102603729B1 (ko) * | 2018-08-23 | 2023-11-17 | 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 | Jak 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리딘 화합물 및 이의 용도 |
| CN110857304B (zh) * | 2018-08-24 | 2021-05-18 | 北京富龙康泰生物技术有限公司 | Trk抑制剂、其制备方法和用途 |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| CN113271940A (zh) * | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| AU2019394520A1 (en) * | 2018-12-07 | 2021-07-01 | Betta Pharmaceuticals Co., Ltd | Tyrosine kinase inhibitors, compositions and methods there of |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| BR112021016173A2 (pt) | 2019-02-22 | 2021-11-03 | Regeneron Pharma | Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma |
| CN111718351B (zh) * | 2019-03-19 | 2021-10-12 | 华中师范大学 | 含氧取代吡唑并嘧啶化合物和药物组合物及其应用 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN111848626B (zh) * | 2019-04-30 | 2021-11-30 | 江苏柯菲平医药股份有限公司 | Trk激酶抑制剂及其用途 |
| CN112867717B (zh) * | 2019-05-08 | 2023-01-10 | 浙江同源康医药股份有限公司 | 用作激酶抑制剂的化合物及其应用 |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| KR20210061202A (ko) | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| CN111138437B (zh) * | 2019-12-04 | 2021-03-05 | 杭州华东医药集团新药研究院有限公司 | 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途 |
| AU2020402942B2 (en) * | 2019-12-13 | 2023-05-11 | Scinnohub Pharmaceutical Co., Ltd | Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021148010A1 (zh) * | 2020-01-22 | 2021-07-29 | 南京明德新药研发有限公司 | 吡唑并杂芳环类化合物及其应用 |
| JP2023512366A (ja) | 2020-02-03 | 2023-03-27 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 |
| AU2020428591B2 (en) * | 2020-02-13 | 2024-05-23 | Zhuhai United Laboratories Co., Ltd. | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases |
| EP4110772A4 (en) | 2020-02-26 | 2024-04-03 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE |
| CN114437077B (zh) * | 2020-11-04 | 2024-01-30 | 浙江同源康医药股份有限公司 | 用作激酶抑制剂的化合物及其应用 |
| WO2021249450A1 (zh) * | 2020-06-11 | 2021-12-16 | 贝达药业股份有限公司 | 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途 |
| CN111777549A (zh) * | 2020-07-07 | 2020-10-16 | 中瀚(齐河县)生物医药科技有限公司 | 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺 |
| AU2021311131B2 (en) | 2020-07-24 | 2026-02-19 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| CN113563343B (zh) * | 2020-07-27 | 2022-05-24 | 杭州邦顺制药有限公司 | 取代的吡唑并[1,5-a]嘧啶化合物及其用途 |
| CN112645955B (zh) * | 2020-12-24 | 2022-11-04 | 四川国康药业有限公司 | 一种[1,2,4]三唑并[4,3-b]哒嗪类化合物及其制备方法和用途 |
| US20240092759A1 (en) * | 2021-01-08 | 2024-03-21 | Yale University | Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use |
| CN115867553B (zh) | 2021-01-09 | 2026-03-06 | 巴格沃克斯研究有限公司 | 作为腺苷2A受体和腺苷2B受体拮抗剂的二氨基吡唑[1, 5-a]并嘧啶-6-腈化合物 |
| CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
| WO2023083362A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗肿瘤的药物 |
| CN114907247A (zh) * | 2022-04-21 | 2022-08-16 | 上海陶术生物科技有限公司 | 吡咯烷中间体及吡咯烷盐类化合物的制备方法 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| WO2025107298A1 (zh) * | 2023-11-24 | 2025-05-30 | 浙江同源康医药股份有限公司 | 晶体、药物组合物及其制备方法和应用 |
Family Cites Families (255)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234143A (en) | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
| DE69422306T4 (de) | 1993-11-30 | 2000-09-07 | G.D. Searle & Co., Chicago | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5430021A (en) | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
| JP3898296B2 (ja) | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬 |
| CA2285264A1 (en) | 1997-04-25 | 1998-11-05 | Michiyo Gyoten | Condensed pyridazine derivatives, their production and use |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6534085B1 (en) | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
| CA2412494C (en) | 2000-06-22 | 2012-10-23 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| CA2975521A1 (en) | 2001-05-30 | 2002-12-05 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| US7662826B2 (en) | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
| US7449488B2 (en) | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| ITMI20021620A1 (it) | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
| JP4024624B2 (ja) * | 2002-08-26 | 2007-12-19 | 富士通株式会社 | 半導体装置の製造方法及び製造装置 |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1880317B (zh) * | 2002-09-04 | 2012-10-10 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| AU2003298942A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
| WO2004082458A2 (en) | 2003-02-21 | 2004-09-30 | The Johns Hopkins University | Tyrosine kinome |
| JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| JP2006522744A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
| US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| US20070042941A1 (en) | 2003-04-28 | 2007-02-22 | Mitsuomi Hirashima | Galectin 9-inducing factors |
| JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| JP2005008581A (ja) * | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| EA009517B1 (ru) | 2003-06-27 | 2008-02-28 | Байер Кропсайенс Аг | Пиразолопиримидины |
| AR045056A1 (es) | 2003-07-15 | 2005-10-12 | Amgen Inc | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| CA2543116A1 (en) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| PE20051046A1 (es) | 2003-11-28 | 2006-01-11 | Novartis Ag | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| MXPA06007017A (es) | 2003-12-18 | 2006-08-31 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidina como agentes antiproliferativos. |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| WO2005068424A1 (en) | 2004-01-20 | 2005-07-28 | Cell Therapeutics Europe S.R.L. | Indolinone derivatives as receptor tyrosine kinase ihibitors |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
| CN1938311A (zh) | 2004-03-30 | 2007-03-28 | 因特蒙公司 | 作为病毒复制抑制剂的大环化合物 |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| PT1812440E (pt) | 2004-11-04 | 2011-01-25 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases |
| JO3088B1 (ar) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| DE102005003687A1 (de) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
| ES2347172T3 (es) | 2005-02-16 | 2010-10-26 | Astrazeneca Ab | Compuestos quimicos. |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| EP1869049B1 (en) | 2005-03-21 | 2009-03-04 | Eli Lilly And Company | Imidazopyridazine compounds |
| CN101208093A (zh) | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | 吡唑-嘧啶衍生物在治疗疼痛中的用途 |
| US20080287437A1 (en) | 2005-05-16 | 2008-11-20 | Astrazeneca Ab | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors |
| CN100406650C (zh) | 2005-06-05 | 2008-07-30 | 徐斌 | 一种抗特大变位的模块式梳型桥梁伸缩缝装置 |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| US20070025540A1 (en) | 2005-07-07 | 2007-02-01 | Roger Travis | Call center routing based on talkativeness |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| EP1910369A1 (en) | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| CN101232871A (zh) | 2005-08-03 | 2008-07-30 | 伊士曼化工公司 | 生育酚聚乙二醇琥珀酸酯粉末及其制备方法 |
| EP1926734A1 (en) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| WO2007022999A1 (en) | 2005-08-25 | 2007-03-01 | Creabilis Therapeutics S.P.A. | Polymer conjugates of k-252a and derivatives thereof |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| BRPI0616985B1 (pt) | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| AR057979A1 (es) | 2005-10-06 | 2008-01-09 | Schering Corp | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. |
| AU2006301966A1 (en) | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| ATE519757T1 (de) * | 2005-10-11 | 2011-08-15 | Centre Nat Rech Scient | 3 hydroxyflavon-derivate zur erkennung und quantifizierung von zell-apoptosen |
| US8372851B2 (en) | 2005-10-21 | 2013-02-12 | Exelixis, Inc. | Pyrazolo pyrimidines as casein kinase II (CK2) modulators |
| WO2007057399A2 (en) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20080108611A1 (en) | 2006-01-19 | 2008-05-08 | Battista Kathleen A | Substituted thienopyrimidine kinase inhibitors |
| WO2007087245A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Ret tyrosine kinase inhibition |
| KR100846988B1 (ko) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
| WO2007103308A2 (en) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| BRPI0709680B8 (pt) | 2006-03-27 | 2021-05-25 | Nerviano Medical Sciences Srl | derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase |
| GB0606805D0 (en) | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| US7389632B2 (en) | 2006-06-10 | 2008-06-24 | Uhlmann Pac-Systeme Gmbh & Co. Kg | Apparatus for distributing small objects in a fill station |
| EP1873157A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| TWI419889B (zh) * | 2006-07-05 | 2013-12-21 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔１，５-ａ〕嘧啶化合物 |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| EP2067039A2 (en) | 2006-09-12 | 2009-06-10 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research | Non-neuroendocrine cancer therapy |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| JP2010508315A (ja) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
| WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| JP2010514695A (ja) | 2006-12-21 | 2010-05-06 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物および方法およびそのための適応症 |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| CA2682016A1 (en) | 2007-03-28 | 2008-10-02 | Inovacia Ab | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| NZ580327A (en) | 2007-04-03 | 2012-02-24 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| EA019524B1 (ru) | 2007-05-04 | 2014-04-30 | Айрм Ллк | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR |
| CA2687909C (en) | 2007-06-21 | 2015-09-15 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
| AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MY150032A (en) | 2007-07-19 | 2013-11-29 | Merck Sharp & Dohme | Heterocyclic amide compounds as protein kinase inhibitors |
| PT2176231T (pt) | 2007-07-20 | 2016-12-09 | Nerviano Medical Sciences Srl | Derivados de indazol substituídos activos como inibidores de quinases |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| EA201000484A1 (ru) | 2007-10-16 | 2010-12-30 | ВАЙЕТ ЭлЭлСи | Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3 |
| EP2214706A1 (en) | 2007-10-23 | 2010-08-11 | Novartis AG | Use of trkb antibodies for the treatment of respiratory disorders |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| CN101970440A (zh) | 2007-11-28 | 2011-02-09 | 先灵公司 | 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类 |
| WO2009071480A2 (en) | 2007-12-04 | 2009-06-11 | Nerviano Medical Sciences S.R.L. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| PE20091326A1 (es) | 2008-01-17 | 2009-09-18 | Irm Llc | Anticuerpos anti-trkb mejorados |
| JP2009203226A (ja) | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤 |
| EP2254886B1 (en) | 2008-03-28 | 2016-05-25 | Nerviano Medical Sciences S.r.l. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| KR101324804B1 (ko) | 2008-05-13 | 2013-11-01 | 아이알엠 엘엘씨 | 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물 |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| ES2554513T3 (es) | 2008-05-23 | 2015-12-21 | Novartis Ag | Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa |
| JP5767965B2 (ja) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症 |
| EP2323664B1 (en) | 2008-07-29 | 2015-01-07 | Nerviano Medical Sciences S.r.l. | Use of a cdk inhibitor for the treatment of glioma |
| JP5746032B2 (ja) | 2008-09-19 | 2015-07-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ３，４−ジヒドロ−２Ｈ−ピロロ［１，２−ａ］ピラジン−１−オン誘導体 |
| WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| WO2010058006A1 (en) | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor for the treatment of mesothelioma |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| EP3266795A1 (en) | 2009-02-12 | 2018-01-10 | Cell Signaling Technology, Inc. | Method for detecting a fig-ros fusion polynucleotide |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| US8546413B2 (en) | 2009-06-15 | 2013-10-01 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011092120A1 (en) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
| ES2594927T3 (es) | 2010-02-18 | 2016-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para prevenir las metástasis cancerosas |
| JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| US8543395B2 (en) | 2010-05-18 | 2013-09-24 | Shazam Entertainment Ltd. | Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization |
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| EP2646468B1 (en) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| WO2012101029A1 (en) | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
| EP2668190B1 (en) | 2011-01-26 | 2016-08-17 | Nerviano Medical Sciences S.r.l. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
| US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN103403002B (zh) | 2011-02-24 | 2016-06-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物 |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| EP2702055A1 (en) | 2011-04-11 | 2014-03-05 | Nerviano Medical Sciences S.r.l. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| JP5970537B2 (ja) | 2011-04-19 | 2016-08-17 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害薬として活性な置換ピリミジニル−ピロール |
| PT2707359T (pt) | 2011-05-12 | 2017-01-09 | Nerviano Medical Sciences Srl | Derivados de indazol substituídos ativos como inibidores de quinase |
| CA2835835C (en) | 2011-05-13 | 2019-04-02 | Array Biopharma Inc. | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
| JP6016915B2 (ja) | 2011-07-28 | 2016-10-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| JP6063945B2 (ja) | 2011-10-07 | 2017-01-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としての４−アルキル置換３，４−ジヒドロピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン誘導体 |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| EP2779833A4 (en) | 2011-11-14 | 2015-03-18 | Tesaro Inc | MODULATION OF SPECIFIC TYROSINE KINASES |
| AU2012351748B2 (en) | 2011-12-12 | 2016-04-14 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| TW201350479A (zh) | 2012-04-26 | 2013-12-16 | Ono Pharmaceutical Co | Ｔｒｋ阻害化合物 |
| JP2013226108A (ja) | 2012-04-27 | 2013-11-07 | Astellas Pharma Inc | 新規ｎｔｒｋ２活性化変異の検出法 |
| ES2751944T3 (es) | 2012-05-23 | 2020-04-02 | Nerviano Medical Sciences Srl | Proceso para la preparación de N-[5-(3,5-difluoro-bencil)-1H-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| BR112015002152B1 (pt) | 2012-08-02 | 2021-04-27 | Nerviano Medical Sciences S.R.L. | Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos |
| EP2890815B1 (en) | 2012-08-31 | 2019-03-20 | The Regents of the University of Colorado | Methods for diagnosis and treatment of cancer |
| JP6513567B2 (ja) | 2012-09-07 | 2019-05-15 | エクセリクシス， インク． | 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤 |
| US20140084039A1 (en) | 2012-09-24 | 2014-03-27 | Electro Scientific Industries, Inc. | Method and apparatus for separating workpieces |
| JP2014082984A (ja) | 2012-10-23 | 2014-05-12 | Astellas Pharma Inc | 新規ｎｔｒｋ２活性化変異の検出法 |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| RS55593B1 (sr) | 2012-11-13 | 2017-06-30 | Array Biopharma Inc | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola |
| WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| MX374242B (es) | 2012-11-13 | 2025-03-05 | Array Biopharma Inc | Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa. |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| CA2877847A1 (en) | 2012-11-29 | 2014-06-05 | Yeda Research And Development Co. Ltd. | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors |
| US9447135B2 (en) | 2012-12-14 | 2016-09-20 | University Of Kentucky Research Foundation | Semi-synthetic mithramycin derivatives with anti-cancer activity |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| AU2014219855B2 (en) | 2013-02-19 | 2017-09-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| WO2014130975A1 (en) | 2013-02-22 | 2014-08-28 | Bastian Boris C | Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets |
| WO2014134096A1 (en) | 2013-02-27 | 2014-09-04 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
| WO2014151117A1 (en) | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| WO2014150751A2 (en) | 2013-03-15 | 2014-09-25 | Novartis Ag | Biomarkers associated with brm inhibition |
| WO2014152777A2 (en) | 2013-03-15 | 2014-09-25 | Insight Genetics, Inc. | Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| AR095308A1 (es) | 2013-03-15 | 2015-10-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento |
| US10072298B2 (en) | 2013-04-17 | 2018-09-11 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
| AU2014254394B2 (en) | 2013-04-17 | 2020-06-18 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
| EP2997030B1 (en) | 2013-05-14 | 2017-08-09 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| CN105228983A (zh) | 2013-05-30 | 2016-01-06 | 普莱希科公司 | 用于激酶调节的化合物及其适应症 |
| EP3019489A4 (en) | 2013-07-11 | 2016-12-28 | Betta Pharmaceuticals Co Ltd | MODULATORS OF TYROSINE KINASE PROTEIN AND METHODS OF USE |
| US10705087B2 (en) | 2013-07-26 | 2020-07-07 | Japanese Foundation For Cancer Research | Detection method for NTRK3 fusion |
| EP3027654B1 (en) | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
| EP3628749A1 (en) | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
| WO2015039006A1 (en) | 2013-09-16 | 2015-03-19 | The General Hospital Corporation | Methods of treating cancer |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| SI3057969T1 (sl) | 2013-10-17 | 2018-10-30 | Blueprint Medicines Corporation | Sestavki, uporabni za zdravljenje motenj, povezanih s KIT |
| CN105848654B (zh) | 2013-10-24 | 2018-10-02 | 乔治城大学 | 用于治疗癌症的方法和组合物 |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| JPWO2015064621A1 (ja) | 2013-10-29 | 2017-03-09 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| KR101723997B1 (ko) | 2014-02-05 | 2017-04-06 | 브이엠 온콜로지 엘엘씨 | 화합물의 조성물 및 이의 용도 |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| US20170044621A1 (en) | 2014-04-18 | 2017-02-16 | Blueprint Medicines Corporation | Met fusions |
| WO2015161274A1 (en) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Pik3ca fusions |
| MA40434B1 (fr) | 2014-05-15 | 2019-09-30 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka |
| WO2015183836A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
| WO2015183837A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
| WO2015184443A1 (en) | 2014-05-30 | 2015-12-03 | The Regents Of The University Of Colorado | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
| WO2015191666A2 (en) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Raf1 fusions |
| EP3155118A1 (en) | 2014-06-10 | 2017-04-19 | Blueprint Medicines Corporation | Pkn1 fusions |
| WO2016011144A1 (en) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Tert fusions |
| US10370725B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | FGR fusions |
| US10370724B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | PRKC fusions |
| US20160032404A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US10399959B2 (en) | 2014-08-18 | 2019-09-03 | Ono Pharmaceutical Co., Ltd. | Acid-addition salt of Trk-inhibiting compound |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| KR102562866B1 (ko) | 2014-11-14 | 2023-08-04 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체 |
| CN113354649B (zh) | 2014-11-16 | 2024-12-10 | 阵列生物制药公司 | 一种新的晶型 |
| EP3221700B1 (en) | 2014-11-18 | 2022-06-22 | Blueprint Medicines Corporation | Prkacb fusions |
| CA2971024C (en) | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| IL294183B2 (en) | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| MA43943A (fr) | 2015-05-29 | 2018-12-12 | Ignyta Inc | Compositions et procédés pour traiter des patients avec des cellules mutantes rtk |
| HK1253093A1 (zh) | 2015-06-01 | 2019-06-06 | Loxo Oncology Inc. | 诊断和治疗癌症的方法 |
| AU2015101722A4 (en) | 2015-06-19 | 2016-05-19 | Macau University Of Science And Technology | Oncogenic ros1 and alk kinase inhibitor |
| US9782400B2 (en) | 2015-06-19 | 2017-10-10 | Macau University Of Science And Technology | Oncogenic ROS1 and ALK kinase inhibitor |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US20170224662A1 (en) | 2016-01-22 | 2017-08-10 | The Medicines Company | Aqueous Formulations and Methods of Preparation and Use Thereof |
| JPWO2017155018A1 (ja) | 2016-03-11 | 2019-01-17 | 小野薬品工業株式会社 | Ｔｒｋ阻害剤抵抗性の癌治療剤 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| FI3439662T3 (fi) | 2016-04-04 | 2024-09-04 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita |
| CN109475545A (zh) | 2016-04-19 | 2019-03-15 | 埃克塞里艾克西斯公司 | 三阴性乳腺癌治疗方法 |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| WO2017201156A1 (en) | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2019084285A1 (en) | 2017-10-26 | 2019-05-02 | Qian Zhao | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR |
-
2010
- 2010-07-08 AR ARP100102489A patent/AR077468A1/es not_active Application Discontinuation
- 2010-07-09 MY MYPI2012000087A patent/MY162180A/en unknown
- 2010-07-09 RU RU2016114128A patent/RU2016114128A/ru not_active Application Discontinuation
- 2010-07-09 AU AU2010271270A patent/AU2010271270C1/en not_active Ceased
- 2010-07-09 UY UY0001032782A patent/UY32782A/es not_active Application Discontinuation
- 2010-07-09 CN CN201610388362.1A patent/CN106008523B/zh not_active Expired - Fee Related
- 2010-07-09 RU RU2012104493/04A patent/RU2584157C2/ru not_active IP Right Cessation
- 2010-07-09 CN CN201811635133.0A patent/CN110003214B/zh not_active Expired - Fee Related
- 2010-07-09 MX MX2015000539A patent/MX364157B/es unknown
- 2010-07-09 KR KR1020177027763A patent/KR101933123B1/ko not_active Expired - Fee Related
- 2010-07-09 WO PCT/US2010/041538 patent/WO2011006074A1/en not_active Ceased
- 2010-07-09 EP EP10732606.8A patent/EP2451812B1/en active Active
- 2010-07-09 CN CN201080040095.XA patent/CN102596957B/zh not_active Expired - Fee Related
- 2010-07-09 SG SG2012001178A patent/SG177553A1/en unknown
- 2010-07-09 CA CA3013618A patent/CA3013618C/en active Active
- 2010-07-09 TW TW099122737A patent/TWI503321B/zh not_active IP Right Cessation
- 2010-07-09 SG SG10201603095TA patent/SG10201603095TA/en unknown
- 2010-07-09 ES ES10732606.8T patent/ES2655899T3/es active Active
- 2010-07-09 MX MX2012000513A patent/MX2012000513A/es active IP Right Grant
- 2010-07-09 KR KR1020187037088A patent/KR101997055B1/ko not_active Expired - Fee Related
- 2010-07-09 ES ES17199899T patent/ES2774654T3/es active Active
- 2010-07-09 US US13/382,858 patent/US8791123B2/en active Active
- 2010-07-09 CA CA2767648A patent/CA2767648C/en active Active
- 2010-07-09 JP JP2012519764A patent/JP5716021B2/ja not_active Expired - Fee Related
- 2010-07-09 KR KR1020127003458A patent/KR101784977B1/ko not_active Expired - Fee Related
- 2010-07-09 EP EP17199899.0A patent/EP3299372B1/en active Active
- 2010-07-09 NZ NZ598086A patent/NZ598086A/en not_active IP Right Cessation
-
2012
- 2012-01-08 IL IL217414A patent/IL217414A/en not_active IP Right Cessation
- 2012-01-09 CL CL2012000059A patent/CL2012000059A1/es unknown
- 2012-02-08 CR CR20120065A patent/CR20120065A/es unknown
- 2012-02-08 CO CO12022116A patent/CO6612183A2/es active IP Right Grant
- 2012-02-09 ZA ZA2012/00982A patent/ZA201200982B/en unknown
- 2012-12-17 CR CR20120641A patent/CR20120641A/es unknown
-
2014
- 2014-07-01 US US14/321,246 patent/US9682979B2/en active Active
-
2015
- 2015-01-09 JP JP2015002767A patent/JP6114765B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-09 US US15/401,913 patent/US9782415B2/en active Active
- 2017-01-09 US US15/401,895 patent/US9796724B2/en active Active
- 2017-02-08 JP JP2017020927A patent/JP2017082004A/ja not_active Withdrawn
- 2017-10-04 US US15/724,601 patent/US10251889B2/en active Active
-
2019
- 2019-04-08 US US16/377,514 patent/US10758542B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532888A5 (https=) | ||
| RU2012104493A (ru) | Замещенные соединения пиразоло [1,5-a] пиримидина как ингибиторы киназы trk | |
| JP2012503018A5 (https=) | ||
| JP2019537571A5 (https=) | ||
| JP2021535134A5 (https=) | ||
| RU2015154987A (ru) | Гетероциклические производные | |
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| JP2022520811A5 (https=) | ||
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| JP2019533694A5 (https=) | ||
| JP2019038820A5 (https=) | ||
| JP2023536164A5 (https=) | ||
| JP2017530999A5 (https=) | ||
| RU2016108753A (ru) | Ингибиторы ферментов | |
| RU2009101911A (ru) | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы | |
| JP2011500806A5 (https=) | ||
| JP2021512143A5 (https=) | ||
| RU2016137674A (ru) | Производные пиперидиндиона | |
| JP2017525757A5 (https=) | ||
| JP2013512900A5 (https=) | ||
| JP2017505794A5 (https=) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2015133171A (ru) | Бензиламиновые производные |